Avidity Partners Management LP Neurocrine Biosciences Inc Transaction History

Avidity Partners Management LP

  • $445 Million
  • Q1 2025

A detailed history of Avidity Partners Management LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Avidity Partners Management LP holds 85,700 shares of NBIX stock, worth $11 Million. This represents 2.13% of its overall portfolio holdings.

Number of Shares
85,700
Previous 220,400 61.12%
Holding current value
$11 Million
Previous $30.1 Million 68.49%
% of portfolio
2.13%
Previous 3.4%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025
SELL
$107.22 - $153.29 $14.4 Million - $20.6 Million
-134,700 Reduced 61.12%
85,700 $9.48 Million
Q4 2024

Feb 14, 2025
SELL
$111.62 - $139.44 $26.7 Million - $33.4 Million
-239,600 Reduced 52.09%
220,400 $30.1 Million
Q3 2024

Nov 14, 2024
SELL
$114.58 - $153.15 $3.55 Million - $4.75 Million
-31,000 Reduced 6.31%
460,000 $53 Million
Q2 2024

Aug 14, 2024
SELL
$130.86 - $143.19 $5.95 Million - $6.52 Million
-45,500 Reduced 8.48%
491,000 $67.6 Million
Q1 2024

May 15, 2024
SELL
$130.4 - $143.74 $15.8 Million - $17.5 Million
-121,500 Reduced 18.47%
536,500 $74 Million
Q4 2023

Feb 14, 2024
BUY
$106.07 - $132.76 $625,813 - $783,284
5,900 Added 0.9%
658,000 $86.7 Million
Q3 2023

Nov 14, 2023
SELL
$94.02 - $117.1 $1.24 Million - $1.55 Million
-13,216 Reduced 1.99%
652,100 $73.4 Million
Q2 2023

Aug 14, 2023
SELL
$89.53 - $104.87 $13.5 Million - $15.8 Million
-150,384 Reduced 18.44%
665,316 $62.7 Million
Q1 2023

May 15, 2023
SELL
$94.11 - $123.02 $90.8 Million - $119 Million
-964,300 Reduced 54.17%
815,700 $82.6 Million
Q4 2022

Feb 14, 2023
SELL
$106.72 - $127.06 $8.08 Million - $9.62 Million
-75,700 Reduced 4.08%
1,780,000 $213 Million
Q3 2022

Nov 14, 2022
BUY
$92.03 - $107.81 $35.7 Million - $41.8 Million
388,100 Added 26.44%
1,855,700 $197 Million
Q2 2022

Aug 15, 2022
BUY
$75.79 - $100.07 $23.3 Million - $30.8 Million
307,600 Added 26.52%
1,467,600 $143 Million
Q1 2022

May 16, 2022
SELL
$72.45 - $94.81 $7.25 Million - $9.48 Million
-100,000 Reduced 7.94%
1,160,000 $109 Million
Q4 2021

Feb 14, 2022
BUY
$79.65 - $106.22 $32.7 Million - $43.7 Million
411,100 Added 48.43%
1,260,000 $107 Million
Q3 2021

Nov 15, 2021
BUY
$86.18 - $99.03 $14.5 Million - $16.6 Million
167,900 Added 24.65%
848,900 $81.4 Million
Q2 2021

Aug 16, 2021
BUY
$89.43 - $102.27 $14.3 Million - $16.3 Million
159,600 Added 30.61%
681,000 $66.3 Million
Q1 2021

May 17, 2021
BUY
$87.57 - $119.4 $19.4 Million - $26.4 Million
221,400 Added 73.8%
521,400 $50.7 Million
Q4 2020

Feb 16, 2021
BUY
$86.91 - $108.33 $26.1 Million - $32.5 Million
300,000 New
300,000 $28.8 Million
Q3 2020

Nov 16, 2020
SELL
$96.16 - $135.15 $17.8 Million - $25 Million
-185,100 Closed
0 $0
Q2 2020

Aug 14, 2020
BUY
$85.09 - $130.36 $7.41 Million - $11.4 Million
87,100 Added 88.88%
185,100 $22.6 Million
Q1 2020

Jun 17, 2020
BUY
$75.11 - $113.76 $7.36 Million - $11.1 Million
98,000 New
98,000 $8.48 Million
Q1 2020

May 15, 2020
SELL
$75.11 - $113.76 $2.48 Million - $3.75 Million
-33,000 Closed
0 $0
Q4 2019

Jun 17, 2020
BUY
$86.8 - $118.57 $2.86 Million - $3.91 Million
33,000 New
33,000 $3.55 Million

Others Institutions Holding NBIX

# of Institutions
651
Shares Held
96.1M
Call Options Held
800K
Put Options Held
565K
View Full List

About NEUROCRINE BIOSCIENCES INC

NBIX Quotes by TradingView
  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12.3B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Avidity Partners Management LP Portfolio

Follow Avidity Partners Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email